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A B S T R A C T
Classical risk factors for the development of atherosclerosis include hypercholester-
olemia, hypertension, smoking, and diabetes. When the atheromatous plaque erodes 
or ruptures, local thrombosis develops which leads to partial or complete vessel occlu-
sion with its attendant potentially catastrophic consequences. Thus, the term athero-
thrombotic disease has been adopted. However, inflammation is also a major con-
tributor to the initiation and evolution of this process and has not been adequately 
addressed. The concept that atherosclerosis is an inflammatory disease has caused a 
paradigm shift in our understanding of its pathogenesis. Recent convincing evidence 
has accumulated that inflammation plays a fundamental role in atherothrombosis and 
the associated risk may be equal to that of hyperlipidemia. Based on this concept, new 
biomarkers and novel anti-inflammatory and immune therapies are being currently 
tested for managing atherosclerotic cardiovascular disease.
I N T R O D U C T I O N
Atherosclerosis is derived from the Greek words ‘athera’ (Aθήρα) meaning soft 
gruel-like (porridge-/mush-/paste-like) fatty deposit and ‘sclerosis’ which means hard-
ening. Atherosclerosis is a pathological process that affects large- and medium-sized 
arteries and causes coronary artery disease (angina pectoris and myocardial infarc-
tion), cerebrovascular disease (ischemic stroke and vascular dementia) and peripheral 
vascular disease (intermittent claudication and gangrene). Atherosclerosis is a chronic 
cumulative disease progressing over years. It is characterized by atherosclerotic plaques 
formed in the wall of the vessels, consisting of necrotic cores, calcified regions, ac-
cumulated modified lipids, inflamed smooth muscle cells (SMCs), endothelial cells, 
leukocytes, and foam cells.1,2 Lesions begin early as fatty streaks and progress into 
pathologic lesions under the influence of both genetic and lifestyle insults. Classical 
risk factors include hypercholesterolemia, hypertension, smoking and diabetes. When 
the atheromatous plaque erodes or ruptures, the coagulation cascade is activated and 
local thrombosis occurs leading to partial or complete vessel occlusion locally or at a 
distance. Thus, the term athero-thrombotic disease has been adopted. However, inflam-
mation is also a major contributor to the initiation and evolution of this process and has 
not been adequately addressed. The concept that atherosclerosis is an inflammatory 
EDITORIAl
1First Department of Cardiology, 
Evagelismos General Hospital of 
Athens, Athens; 
2Patras University School of Medicine, 
Patras;  
3Onassis Cardiac Surgery Center, 
Athens, Greece
HOSPITAL CHRONICLES 2012, 7(4): 195–201
Correspondence to: 
Antonis S. Manolis, MD, First 
Department of Cardiology, 
Evagelismos Hospital, Athens, 
Greece; e-mail: asm@otenet.gr
Manuscript received September 13, 2012; 
Revised manuscript accepted September 
28, 2012
KEy WORDS: atherosclerosis; coronary 
thrombosis; inflammation; immunity; 
autoimmune disease; cardiovascular 
disease; acute coronary syndromes; 
myocardial infarction; ischemic stroke
AbbreviAtions
CAD = coronary artery disease
CRP = C-reactive protein
GWAS = genome-wide associated studies 
HDL = high density lipoprotein
IL = interleukin 
LDL = low density lipoprotein
Lp (a) = lipoprotein a
Lp-PLA2 = lipoprotein associated 
phospholipase A2 
MMPs = matrix metaloproteinases 
ROS = reactive oxygen species 
SMCs = smooth muscle cells 
TGF = tissue growth factor
Th = T-helper (cells)
Conflict of Interest: none declared
196
HOSPITAL CHRONICLES 7(4), 2012
disease has caused a paradigm shift in our understanding of 
its pathogenesis.1,3 It thus appears that the early stages of the 
disease process simulate chronic inflammation similar to that 
noted in other diseases in other organs, such as rheumatoid 
arthritis, liver cirrhosis or pulmonary fibrosis.4-6 The early 
stages are also similar to the reaction observed in asthma 
(infiltration by T lymphocytes and monocytes, converted into 
macrophages, followed by proliferation of fibrous tissue).5 
A T H E R O S C l E R O S I S :  
A N  I N F l A M M A T O R y  D I S E A S E
Information that atherosclerosis is an inflammatory disease 
comes from several facts and findings.1-4 There is immune activ-
ity in the atheromatous plaque, with the presence of T cells and 
macrophages, human leukocyte antigen, costimulatory factors, 
and cytokines. A systemic response is elicited with increase in 
C-reactive protein (CRP), interleukin (IL)-1, IL-6, and other 
antibodies. There is a genetic association detected between al-
leles of immune and inflammatory genes. There is information 
on immunopathogenesis of major effects of immune factors 
in model organisms. Inflammation in coronary arteries leads 
to release of inflammatory mediators into the circulation and 
triggers acute phase reaction in the liver. 
Inflammation is typically triggered when bacterial patho-
gens invade the organism. Both the innate (macrophages, 
endothelial cells and other cells) and the adaptive (T and B 
cells) immune systems are involved. Macrophages and T cells 
accumulate at sites of LDL retention in the forming atheroscle-
rotic plaque, which is a site of immune inflammation. Toll-like 
receptors recognizing pathogen molecules trigger inflamma-
tion. Toll-like receptors can also recognize danger-associated 
endogenous molecules, like stress inducible cytosolic heat 
shock proteins, components of oxidized LDL, nucleic acids, 
etc. The innate immune response of macrophages is initiated 
by cholesterol crystals that activate a component of the innate 
immune system, the inflammasome, which is a multiprotein 
oligomer consisting of caspase 1, PYCARD (apoptosis-
associated speck-like protein), NALP protein [a nucleotide 
oligomerization domain (NOD)-like receptor] and sometimes 
caspase 5, expressed in myeloid cells.7 The activated T cell can 
instruct the B cell to make antibodies to its cognate antigen 
and activate the macrophage to promote inflammation. 
Interleukin (IL)-1 consists of two distinct ligands, IL-
1alpha and IL-1beta, with similar biological activities that 
signal through the IL-1 type I receptor (IL-1RI). A naturally 
occurring IL-1 receptor antagonist (IL-1Ra) binds to IL-1RI 
without initiating signal transduction and prevents IL-1 
signaling, competitively inhibiting IL-1-mediated responses. 
Emerging evidence suggests that interleukin-1 (IL-1) may 
promote the formation of atheromatous lesions, enhance 
vascular inflammation, and trigger plaque destabilization.8 
Following acute myocardial infarction, IL-1 critically regulates 
the inflammatory response and is implicated in adverse remod-
eling by enhancing expression of matrix metalloproteinases. 
Furthermore, current available data also raise the possibility 
that IL-1 inhibitors (such as anakinra, a nonglycosylated re-
combinant human IL-1Ra) may be of clinical use in certain 
cardiovascular patients. On the other hand, lack of interleukin 
1β or NLRP 3 inflammasome of innate immunity impressively 
reduces atherosclerosis. Finally, there is recent evidence for 
participation of mast cells in the process of atherosclerosis, 
as they release vasoactive substances and may be involved in 
several atherogenic actions, observations that may have some 
therapeutic implications.3 
Activated T cells attach to the vascular surface via cell 
adhesion molecules and migrate into the intima. 9 When inter-
acting with protein antigens (oxidized LDL, heat shock protein 
60, and/or bacterial antigens), T helper (Th)-1 cells are formed 
which release pro-inflammatory markers and initiate a cascade 
of inflammation leading to atheromatous lesion formation and 
plaque vulnerability. Virtually, the atheroma is a Th1 lesion; 
Th1 cells are prevalent in human lesions; a local Th1 response 
to LDL autoantigen promotes atherosclerosis;10 lack of Th1 
cells reduces atherosclerosis in hypercholesterolemic mice. T 
helper 1-associated cytokines such as IL-1, interferon-γ, IL-6 
and IL-12 within the atherosclerotic lesion, are proatherogenic 
and lead to enhanced activation and recruitment of T cells, 
macrophages and dendritic cells in the plaque. A disturbed 
balance between Th-1 and Th-2 cytokines has long been con-
sidered as the underlying cause of the autoinflammatory pa-
thology in atherosclerosis. Th2 cytokines such as IL-5 and IL-10 
are antiatherogenic and may counteract the Th1 cytokines. In 
general, both lack of innate (inflammasome) or adaptive im-
munity (B and T cells) in mice leads to dramatic reduction of 
atherosclerosis, without affecting cholesterol levels. 
There is also a role of cytotoxic T cells in atherosclerosis. 
There is abundant T cell death in atherosclerotic plaque. 
CD8+ T cells kill target cells via cell-cell contact. A total of 
30% of T cells in human plaques are CD8+ cells. Activation 
of CD8+ T cells to an artificial antigen on vascular smooth 
muscle cells is strongly pro-atherogenic in mice. CD137 
ligand, a TNF-like molecule, which is also found in human 
atherosclerotic plaques, promotes recruitment and activation 
of cytotoxic CD8+ T cells. 
Several pathophysiologic observations in both humans and 
animals have led to the hypothesis of response-to-injury for 
atherosclerosis, and recent data emphasize endothelial dysfunc-
tion rather than denudation, as the initiating stage in a chronic 
inflammatory atherosclerotic process (Fig. 1).1,3 Possible 
causes of such endothelial dysfunction may comprise elevated 
and modified (oxidized or glycated) LDL; free radicals from 
cigarette smoking, hypertension, and diabetes mellitus; genetic 
abnormalities; increased homocysteine; infectious agents such 
as herpesviruses or Chlamydia pneumonia; and combinations 
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of these or other factors.1
Lipoprotein (a) resembles LDL but possesses a unique gly-
coprotein apolipoprotein a (apo a) group and exists in different 
isoforms with kringle domains that are similar to those found 
in plasminogen. An elevated level of Lp (a) is a risk factor for 
atherosclerosis because it promotes inflammation. Its activity 
appears to be facilitated by increased levels of homocysteine 
and LDL and by diabetes. Lp (a) induces proinflammatory 
molecules via its apo a, among which is the tissue factor that is 
also prothrombotic. Animal studies show that apo a decreases 
the amount of plasmin and tissue growth factor beta (TGF-β), 
whose physiologic role is to limit inflammatory responses and 
prevent the migration and proliferation of smooth muscle cells. 
Inflammation can also be implicated in the occurrence of 
plaque rupture and development of thrombosis, which can lead 
to acute myocardial infarction (Fig. 1).1,11 When activated in 
the intima, the T lymphocytes produce pro- inflammatory cy-
tokines, inducing production of extracellular matrix-degrading 
metaloproteinases (MMPs) (which weaken the fibrous cap 
of the plaque) and of the potent procoagulant tissue factor 
(which initiates the coagulation cascade). Inflammation also 
inhibits the production or promotes degradation of collagen 
and hence further influences the strength and stability of the 
fibrous cap. Thus, inflammation contributes to all phases of 
atherosclerosis, from its initiation to its ultimate complication 
of thrombosis (Fig. 1, Table 1). Presence of multiple types of 
vulnerable plaques suggests that atherosclerosis is a diffuse 
inflammatory process. 11 
G E N E T I C  S T U D I E S
Recent genome-wide associated studies (GWAS) have 
identified novel loci associated with coronary artery disease 
(CAD) or myocardial infarction. Interestingly, recent studies 
identified novel inflammation-related loci associated with 
CAD risk, including a region near the major histocompatibility 
complex (MHC) on chromosome 6p21 and the chemokine 
ligand 2 (CXCL2) on chromosome 4, encoding an athero-
protective chemokine.12-14 Both GWAS and candidate gene 
 Early Plaque Formation Stable Plaque
 Vulnerable Plaque Plaque Rupture
• Endothelial dysfunction: ↑ endothelial permeability /up-
regulation of leukocyte & endothelial adhesion molecules 
/ migration of leukocytes into the artery wall, which is 
mediated by oxidized LDL, etc
• Smooth-muscle migration
• T-cell activation
• Foam cell formation (lipid-laden monocytes & 
macrophages)
• Platelet adherence and aggregation
• Repeated cycles of inflammation lead to accumulation of 
macrophages 
• Some macrophages get necrosed and mix with lipid and 
debris and produce the necrotic core 
• Smooth muscle cells (SMCs) proliferate & migrate in 
lesion to form the fibrous cap of advanced but stable 
atherosclerotic lesion 
• Fibrous cap seals off the lesion from the lumen
• Healing or fibrous response to injury
• Cytokine network promotes development of Th1 pathway, which is proinflammatory & induces macrophage activation, superoxide 
production, and protease activity 
• This potent inflammatory cascade favors transition from stable plaque to unstable or ruptured plaque 
• Rupture or ulceration of the fibrous plaque usually occurs at sites of thinning of the fibrous cap that covers the atherosclerotic lesion 
and rapidly lead to thrombosis 
• Thinning of the fibrous cap is produced from the continuing influx and activation of macrophages, which release metalloproteinases 
and other proteolytic enzymes 
• These enzymes cause degradation of the matrix, which can lead to hemorrhage from the vasa vasorum or from the lumen and can 
result in thrombus formation and partial or complete occlusion of the artery leading to ACS
FIGURE 1. Role of the Deleterious Effect of Inflammation in Atherosclerosis (see text for discussion). ACS = acute coronary syn-
dromes; LDL = low dense lipoprotein; SMCs = smooth muscle cells; Th = T helper (cells).
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TABlE 1. Factors Determining Atheromatous Plaque Vulnerability, Rupture and Myocardial Infarction
large lipid 
necrotic core
Role of core as a 
vulnerability factor still 
debated 
Some have found larger 
pool of extractable lipid 
in symptomatic than in 
asymptomatic patients
Thin fibrous cap Its resistance depends on 
presence of functioning 
SMCs & related 
extracellular matrix that 
maintains the fibrous cap
Inflammatory 
activity in the 
plaque
Evolution of atheromas 
modulated by innate & 
adaptive immune responses 
When selective recruitment/ 
activation of Th1 T cells is 
triggered in plaque, a potent 
inflammatory cascade is 
initiated
Th1 T cells release IFN-γ, 
playing a crucial role in 
atherosclerosis
IFN-γ activates 
macrophages, promotes 
pro-coagulant protein & 
MMP secretion, inhibits 
SMC proliferation, & 
downregulates α-actin & 
collagen expression
Adventitia 
Inflammation
Lymphocytes, macrophages, 
& mast cells have been 
found in contact with 
sensory nerve fibers
Diffuse 
inflammation & 
vulnerability
Presence of multiple 
vulnerable plaques in 
coronary tree
Presence of active 
multicentric inflammatory 
infiltrate in coronary vessels 
in fatal MI
Increased MPO activity in 
coronary vessels in unstable 
angina
Activated T cells 
found in peri-MI area 
& remote regions in 
patients with a first MI
Expression of 
factors that 
weaken  
the fibrous cap 
Cell migration into the 
lesion (T cells, foam cells, 
macrophages)
Proliferation of elements 
in the lesion (cells, matrix-
degrading enzymes, 
cytokines, growth factors, 
oxidative excess)
Impaired NO function/ 
Production & degradation 
of the extracellular matrix 
(proteases/ MMPs, 
cytokines, ROS)
Apoptosis of smooth 
muscle cells
Physical forces 
acting on fibrous 
cap 
Circumferential force 
(induced by blood pressure)
Shear stress Vasospasm
Newly formed 
microvessels 
(vasa vasorum) / 
Neoangiogenesis
These vessels are weak and 
could be responsible for 
intraplaque hemorrhage
Intraplaque 
hemorrhage
From cracks or fissures 
at luminal surface at its 
thinnest portion, or from 
rupture of vasa vasorum
Contributes to growth of the 
lipid necrotic core
Facilitates a more rapid 
progression & rupture of 
plaque
MI = myocardial infarction; MMPs = matrix metaloproteinases; MPO = myeloperoxidase; NO = nitric oxide; ROS = reactive oxygen species; 
SMC = smooth muscle cell; Th = T helper (cells)
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studies lend support to the hypothesis that proinflammatory 
pathways, involving both innate and adaptive immunity, play 
a causal role in CAD. The ABO locus, also linked to CAD 
risk by the GWAS approach, is related to multiple pheno-
types, including plasma interleukin-6 (IL-6) levels. Relevant 
to inflammation, the 9p21 CAD risk locus appears to play a 
role in interferon-gamma signalling. Candidate gene studies 
also support a causative role of inflammation pathways in 
atherosclerosis. Of note, a common loss of function coding 
variant in the IL-6 receptor gene (IL6R) is associated with a 
reduction in CAD risk.13
A T H E R O P R O T E C T I O N
However, not all immunity is pro-atherogenic. There is a 
defense mechanism fighting back. Pro-atherogenic immunity 
can be modulated by inhibitory stimuli. LDL immunization 
or immunomodulatory intravenous immunoglobulin reduce 
atherosclerosis. Subpopulations of B and T cells are athero-
protective. As discussed earlier, Th2 cytokines such as IL-5 and 
IL-10 are antiatherogenic and may counteract the Th1 cyto-
kines. Transforming growth factor beta (TGF-β) derived from 
T-cells has a protective effect. Regulatory T-cells use TGF-β to 
suppress atherosclerosis. Thus, several therapeutic opportuni-
ties may emerge by taking advantage of knowledge expansion 
regarding blocking antibodies to LDL/oxidized LDL, targeting 
T regulatory cells for atheroprotective vaccination, blocking 
inflammatory mediators (cytokines, leukotrienes) and/or 
immune activation (CD137, etc) or using anti-inflammatory 
cytokines as atheroprotecive agents. Interleukin-1 has been 
implicated to promote the formation of atheromatous lesions, 
enhance vascular inflammation, and trigger plaque destabi-
lization, raising the possibility that IL-1 inhibitors, such as 
anakinra, a nonglycosylated recombinant human IL-1Ra, may 
be clinically useful agents to protect patients with CAD.8 High 
density lipoprotein cholesterol (HDL) inhibits oxidation of 
LDL and blocks the proinflammatory effects of oxidized LDL. 
HDL provides protection against atherosclerosis by promoting 
the activity of antioxidant enzymes. Animal studies also show 
that the key protein of HDL, apolipoprotein A-I, may prevent 
the oxidation of LDL. 
B I O M A R K E R S
Thus, there is compelling evidence that atherosclerosis 
should be regarded as an inflammatory disease principally 
triggered by LDL accumulation. However, inflammation is 
an independent risk factor. This notion that inflammation is 
heavily involved in atherosclerosis has spurred the discovery 
and adoption of inflammatory biomarkers for cardiovascular 
risk prediction (Table 2).15-17 Most of the biomarkers associated 
with atherosclerosis are indeed indicators of inflammatory 
TABlE 2. Biomarkers of Atheromatous Plaque Inflammation
Markers of 
Inflammation Metabolic Markers lipid Markers
Markers of Plaque 
Neovascularization & 
Thrombosis
Markers of 
Endothelial 
Dysfunction
Oxidative 
Stress 
Markers
CRP Insulin LDL-C Angiogenic cytokines 
(placental growth factor, 
stroma-derived factor 1)
NO MPO
Pentraxin 3 Glucose HDL-C Nicotine ADMA
Soluble CD40 ligand Adipokines (leptin, 
resistin)
oxLDL-C Tissue factor Soluble vascular 
adhesion molecules
TNF Inflammatory 
cytokines (TNF)
Small dense LDL-C vWF
Cellular adhesion 
molecules (ICAM-1, 
VCAM-1
Adiponectin 
(vasoprotective)
Lp(a) Endothelial 
progenitor cells
Cytokines (IL-1, IL-18) Lp-PLA2
Metalloproteinases
ADMA = asymmetric dimethylarginine; CRP = C-reactive protein; HDL-C = high density lipoprotein cholesterol; ICAM = intercellular adhesion 
molecule; LDL-C = low density lipoprotein cholesterol; Lp(a) = lipoprotein a; IL = interleukin; Lp-PLA2 = lipoprotein phospholipase A2; MPO 
= myeloperoxidase; NO = nitric oxide; oxLDL-C = oxidized LDL cholesterol; TNF = tumor necrosis factor; VCAM = vascular cell adhesion 
molecule; vWF = von Willebrand factor
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response.11 Current inflammatory markers, such as high-sensi-
tivity C-reactive protein (hsCRP), adiponectin, soluble CD40 
ligand, myeloperoxidase, lipoprotein associated phospholipase 
A2 (Lp-PLA2), pentraxin-3, cytokines such as IL-6 and IL-18, 
proteases such as matrix metalloproteinase-9, are informative 
and have generated considerable attention, but their use as a 
screening method is debated. Among them, CRP has emerged 
as a leading biomarker of inflammation for clinical application. 
A N T I - I N F l A M M A T O R y  T H E R A P I E S
Furthermore, anti-inflammatory therapies, e.g. TNF block-
ers, methotrexate, statins, etc, will need to be considered and 
evaluated for their effect on cardiovascular disease.18 Half of 
coronary events are explainable by the presence of traditional 
risk factors (hypercholesterolemia, hypertension, smoking, 
diabetes and metabolic syndrome), however, the other half 
may be related to vascular inflammation, infectious agents 
or other hitherto unknown factors. Thus, although hyper-
cholesterolemia is important in about half the patients with 
cardiovascular disease, other factors need to be considered. 
Atherosclerosis does not result merely from accumulation of 
lipids. Recent evidence has established the important role 
and contribution of inflammation in the pathogenesis of ath-
erosclerosis. We need to selectively modify the deleterious 
components of arterial inflammation and enhance the protec-
tive elements, particularly in those other half of patients with 
cardiovascular disease who do not have hypercholesterolemia.1 
Some standard therapies for CAD prevention (e.g. statins) 
have anti-inflammatory effects that might contribute to their 
clinical benefit; however, prospective studies are necessary 
to test directly the benefits and safety of specific therapies 
targeting the inflammatory process. 
Antioxidants, such as vitamins A, C, and E are known to 
have anti-inflammatory effects on cells.19 Antioxidants seem 
to reduce fatty streaks in arteries of animals and enhance the 
resistance of human LDL (in vitro) to oxidation. High doses 
of vitamin E (α-tocopherol) reduce the release of proinflam-
matory cytokines and decrease adhesion of monocytes to 
endothelium. Vitamin E has been shown to reduce CRP levels 
in individuals with risk factors and in patients with cardiovas-
cular disease. Several biological functions of vitamin E which 
appear to improve the imbalance between oxidative stress 
and antioxidant status, at least in plasma (but not in plaques) 
could account for its protective effect against the development 
of atherosclerosis. It has been proposed that flavonoids may 
act in the arterial wall to suppress LDL oxidation caused by 
macrophages and inflammatory responses, resulting in a de-
cline of CAD. Different classes of flavonoids can be found in 
citrus fruits, herbs, legumes, fruits and vegetables. Flavonoids 
in plants (soybean) and in red wine decrease reactive oxygen 
species (ROS) production and maintain or enhance the bal-
ance between nitric oxide (NO) synthase and endothelin-1 in 
the endothelium, thus helping to maintain normal vascular 
cell functions. Atherosclerosis is lessened in animals fed diets 
containing soy protein compared with those fed diets with 
animal protein.
Current evidence supports the use of statins as an anti-
inflammatory intervention in atherosclerosis due to both LDL-
lowering and direct anti- inflammatory effect. Analysis of the 
PROVE IT–TIMI 22 (Pravastatin or Atorvastatin Evaluation 
and Infection Therapy– Thrombolysis In Myocardial Infarction 
22) study, suggested such dual mechanism of benefit of statin 
therapy, LDL-lowering, and a direct anti-inflammatory effect 
independent of LDL-lowering, reflected by reduction of high-
sensitivity CRP (hsCRP).3,20 Specifically, within the PROVE 
IT–TIMI 22 trial, clinical outcomes were best among statin-
treated patients who not only achieved LDL-C levels below 
70 mg/dl, but who also achieved hsCRP levels below 2 mg/l.3,20
Recently, the U.S. National Institutes of Health (NIH) de-
cided to launch an international multi-center trial, the Cardio-
vascular Inflammation Reduction trial (CIRT), to determine 
whether an anti-inflammatory drug can reduce heart attacks, 
stroke and deaths due to cardiovascular disease in individuals 
at high-risk.21-23 These are patients with a history of myocardial 
infarction within the past 5 years, and who also have diabetes 
type 2 or metabolic syndrome. The trial will randomly assign 
patients to low-dose methotrexate (10-20 mg weekly) for 3-4 
years or placebo. CIRT will enroll 7,000 patients at 350-400 
sites across the US and Canada over the next 2.5 years and 
will follow them for 2-4 years (average 2.5 years). Site selec-
tion will begin in November 2012, and patient recruitment will 
start in March 2013. 
I M M U N I Z A T I O N
Finally, considering atherosclerosis as an autoimmune 
disease, vaccination can provide an alternative treatment for 
atherosclerosis.18,24 Thus, immune therapies are on the horizon 
as the next frontier in the battle against atherosclerosis. Nilsson 
and collaborators are in the process of developing the peptide 
vaccine CVX-210, in a subcutaneous and a nasal version, which 
is made up of fragments of apolipoprotein B, the protein per-
manently associated with LDL, and they are in the planning 
stage of Phase I trials for the subcutaneous form.24 On the 
other hand, for passive immunization in atherosclerosis, there 
are monoclonal antibodies in development, targeting oxidized 
LDL. This includes BI-204 monoclonal antibody, which is in 
Phase II trials. A promising vaccination strategy will be one 
that results in plaque stabilization in addition to reducing 
plaque development. Since atherosclerosis prevails at a very 
young age but only manifests itself later in life, the majority 
of individuals will benefit from a vaccination strategy early in 
life that prevents the development of lesions, while patients 
ATHEROSCLEROSIS: AN INFLAMMATORY DISEASE
201
already afflicted by the disease will benefit from strategies that 
focus on plaque stabilization.
C O N C l U S I O N
Despite the irrefutable utility of traditional risk factors 
(hypercholesterolemia, diabetes, hypertension and smoking) 
in assessing the risk of and guiding our approach to athero-
sclerosis, we are still left with an incomplete picture. Indeed, 
as many as half of cardiovascular events occur in individuals 
with plasma cholesterol concentrations below the recom-
mended levels of 200 mg/dL for total cholesterol and 130 mg/
dL for LDL cholesterol. Recent evidence of the involvement 
of inflammation in atherosclerosis has spawned new interest 
in understanding and solving the enigma of atherosclerosis, 
which plagues the world. Thus, attention has been focused on 
this exciting pathophysiological mechanism of atherosclerosis 
which may provide additional information for cardiovascular 
risk stratification, prediction and cardiovascular disease man-
agement. Shedding further light and providing new insight into 
the mechanism of this unrelenting disease will help evaluate 
the role of emerging biomarkers in the clinical management of 
atherosclerosis and targeting novel therapies. Indeed, evidence 
has accumulated that inflammation plays a fundamental role 
in atherothrombosis and the risk of CAD associated with in-
flammation could be equal to that of hyperlipidemia. Future, 
randomized trials applying the inflammatory hypothesis of 
atherothrombosis will directly test novel anti-inflammatory 
therapies in high risk patients and provide eagerly awaited 
information regarding their efficacy. 
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